Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

Matrilysin-2 expression in colorectal cancer is associated with overall survival of patients

Authors: Qinglin Hu, Chuanjing Yan, Chengfei Xu, Hai Yan, Lian Qing, Yanjun Pu, Zeyou He, Xiaojun Li

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

Tumor recurrence and metastasis are pressing issues of patients with colorectal cancer who receive surgery. Matrilysin-2 (MMP-26) has been proved to play an important role during invasion and metastasis of some human solid tumor. We aimed to investigate the clinical significance and prognostic value of matrilysin-2 in human colorectal cancer. Colorectal cancer and adjacent normal samples from 201 patients were collected. Matrilysin-2 expression level was investigated by immunohistochemistry assay, and its association with overall survival of patients was analyzed by statistical analysis. Results showed that matrilysin-2 expression level significantly elevated in colorectal cancer compared with adjacent normal specimens. Matrilysin-2 expression was also found to be associated with cancer invasion, lymph node metastasis, distant metastasis, and TNM stage. In addition, survival analysis showed that elevated matrilysin-2 expression was associated with poor overall survival of patients. Cox's proportional hazards model indicated that matrilysin-2 was an independent prognostic marker for patients with colorectal cancer. The present study found that the expression of matrilysin-2 increased in colorectal cancer and was associated with tumor progression. It also provided the first evidence that matrilysin-2 expression was an independent prognostic factor for patients with colorectal cancer, which might be a high specific biomarker for colorectal cancer.
Literature
1.
Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Geneti : TIG. 1990;6:121–5.CrossRef
2.
Emonard H, Grimaud JA. Matrix metalloproteinases. A review. Cell Mol Biol. 1990;36:131–53.PubMed
3.
Peng WJ, Yan JW, Wan YN, Wang BX, Tao JH, Yang GJ, et al. Matrix metalloproteinases: a review of their structure and role in systemic sclerosis. J Clin Immunol. 2012;32:1409–14.PubMedCrossRef
4.
Pytliak M, Vargova V, Mechirova V. Matrix metalloproteinases and their role in oncogenesis: a review. Onkologie. 2012;35:49–53.PubMedCrossRef
5.
de Coignac AB, Elson G, Delneste Y, Magistrelli G, Jeannin P, Aubry JP, et al. Cloning of MMP-26. A novel matrilysin-like proteinase. Eur J Biochem / FEBS. 2000;267:3323–9.CrossRef
6.
Park HI, Ni J, Gerkema FE, Liu D, Belozerov VE, Sang QX. Identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor. J Biol Chem. 2000;275:20540–4.PubMedCrossRef
7.
Marchenko GN, Ratnikov BI, Rozanov DV, Godzik A, Deryugina EI, Strongin AY. Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J. 2001;356:705–18.PubMedCentralPubMedCrossRef
8.
Ahokas K, Skoog T, Suomela S, Jeskanen L, Impola U, Isaka K, et al. Matrilysin-2 (matrix metalloproteinase-26) is upregulated in keratinocytes during wound repair and early skin carcinogenesis. J Investig Dermatol. 2005;124:849–56.PubMedCrossRef
9.
Zhao YG, Xiao AZ, Park HI, Newcomer RG, Yan M, Man YG, et al. Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and −4: a putative role in the initiation of breast cancer invasion. Cancer Res. 2004;64:590–8.PubMedCrossRef
10.
Yamamoto H, Vinitketkumnuen A, Adachi Y, Taniguchi H, Hirata T, Miyamoto N, et al. Association of matrilysin-2 (MMP-26) expression with tumor progression and activation of MMP-9 in esophageal squamous cell carcinoma. Carcinogenesis. 2004;25:2353–60.PubMedCrossRef
11.
Ripley D, Tunuguntla R, Susi L, Chegini N. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinase-3 and −4 in normal ovary and ovarian carcinoma. Int J Gynecol Cancer : Off J Int Gynecol Cancer Soc. 2006;16:1794–800.CrossRef
12.
Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000;53:125–30.PubMedCentralPubMedCrossRef
13.
Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41.PubMedCrossRef
14.
15.
Deng SX, An W, Gao J, Yin J, Cai QC, Yang M, et al. Factors influencing diagnosis of colorectal cancer: a hospital-based survey in China. J Dig Dis. 2012;13:517–24.PubMedCrossRef
16.
Chen HM, Weng YR, Jiang B, Sheng JQ, Zheng P, Yu CG, et al. Epidemiological study of colorectal adenoma and cancer in symptomatic patients in China between 1990 and 2009. J Dig Dis. 2011;12:371–8.PubMedCrossRef
17.
Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007;57:168–85.PubMedCrossRef
18.
Sunami E, Tsuno N, Osada T, Saito S, Kitayama J, Tomozawa S, et al. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist. 2000;5:108–14.PubMedCrossRef
19.
Shi M, Yu B, Gao H, Mu J, Ji C. Matrix metalloproteinase 2 overexpression and prognosis in colorectal cancer: a meta-analysis. Mol Biol Rep. 2013;40:617–23.PubMedCrossRef
20.
Yang B, Su K, Gao J, Rao Z. Expression and prognostic value of matrix metalloproteinase-7 in colorectal cancer. Asian Pac J Cancer Prev : APJCP. 2012;13:1049–52.PubMedCrossRef
21.
Chu D, Zhao Z, Zhou Y, Li Y, Li J, Zheng J, et al. Matrix metalloproteinase-9 is associated with relapse and prognosis of patients with colorectal cancer. Annals Surg Oncol. 2012;19:318–25.CrossRef
22.
Yang B, Gao J, Rao Z, Shen Q. Clinicopathological significance and prognostic value of MMP-13 expression in colorectal cancer. Scand J Clin lab Investig. 2012;72:501–5.CrossRef
23.
Yang B, Gao J, Rao Z, Shen Q. Clinicopathological and prognostic significance of α5β1-integrin and MMP-14 expressions in colorectal cancer. Neoplasma. 2013;60:254–61.PubMedCrossRef
24.
Wu T, Li Y, Liu X, Lu J, He X, Wang Q, et al. Identification of high-risk stage II and stage III colorectal cancer by analysis of MMP-21 expression. J Surg Oncol. 2011;104:787–91.PubMedCrossRef
25.
Bister V, Skoog T, Virolainen S, Kiviluoto T, Puolakkainen P, Saarialho-Kere U. Increased expression of matrix metalloproteinases-21 and −26 and TIMP-4 in pancreatic adenocarcinoma. Mod Pathol : Off J U S Can Acad Pathol. 2007;20:1128–40. Inc.CrossRef
26.
Zhao YG, Xiao AZ, Newcomer RG, Park HI, Kang T, Chung LW, et al. Activation of pro-gelatinase b by endometase/matrilysin-2 promotes invasion of human prostate cancer cells. J Biol Chem. 2003;278:15056–64.PubMedCrossRef
Metadata
Title
Matrilysin-2 expression in colorectal cancer is associated with overall survival of patients
Authors
Qinglin Hu
Chuanjing Yan
Chengfei Xu
Hai Yan
Lian Qing
Yanjun Pu
Zeyou He
Xiaojun Li
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1471-y

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

The expression of BTG1 is downregulated in NSCLC and possibly associated with tumor metastasis

Research Article

Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis

Research Article

Prognostic value of matrix metalloproteinase-7 expression in patients with non-small cell lung cancer

Research Article

Clinical significance of S100A2 expression in gastric cancer

Research Article

Association between a functional insertion/deletion polymorphism in IL1A gene and risk of papillary thyroid carcinoma

Research Article

Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits